Johnson & Johnson (NYSE:JNJ) has announced that the investigational antihypertensive drug aprocitentan significantly lowered blood pressure (BP) when used in conjunction with background antihypertensive therapy in the Phase 3 PRECISION study.  Sharing the results in collaboration with Idorsia (OTCMKTS:IDRSF), J&J noted that the drug candidate helped maintain a reduction in blood pressure for 48 weeks. …